Sanofi vs Sarepta Therapeutics, Inc.: Annual Revenue Growth Compared

Sanofi vs Sarepta: A Decade of Revenue Growth Compared

__timestamp	Sanofi	Sarepta Therapeutics, Inc.
Wednesday, January 1, 2014	31999000000	9757000
Thursday, January 1, 2015	34861000000	1253000
Friday, January 1, 2016	34696000000	5421000
Sunday, January 1, 2017	36221000000	154584000
Monday, January 1, 2018	35677000000	301034000
Tuesday, January 1, 2019	37631000000	380833000
Wednesday, January 1, 2020	37369000000	540099000
Friday, January 1, 2021	39175000000	701887000
Saturday, January 1, 2022	45389000000	933013000
Sunday, January 1, 2023	46033000000	1243336000
Monday, January 1, 2024	44286000000

Unlocking the unknown

A Tale of Two Biopharma Giants: Sanofi and Sarepta Therapeutics

In the competitive world of biopharmaceuticals, revenue growth is a key indicator of success. Over the past decade, Sanofi and Sarepta Therapeutics have shown contrasting trajectories. Sanofi, a global leader, has consistently increased its revenue, peaking at approximately $46 billion in 2023, marking a 44% growth since 2014. In contrast, Sarepta Therapeutics, a pioneer in genetic medicine, has experienced a staggering growth rate of over 12,600% during the same period, albeit from a much smaller base. This remarkable rise from $1.25 million in 2015 to $1.24 billion in 2023 highlights Sarepta's rapid expansion and innovation-driven strategy. As these companies continue to evolve, their financial journeys offer valuable insights into the dynamics of the pharmaceutical industry.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025